ClinicalTrials.gg
CompletedNCT02190084Updated Aug 21, 2019

Repetitive Transcranial Magnetic Stimulation for Apathy in Alzheimer's Dementia

A Phase 4 interventional study of Neurostar repetitive transcranial magnetic stimulator in Apathy and Alzheimer's Dementia, sponsored by Central Arkansas Veterans Healthcare System. Completed at 1 site in United States. Open to participants aged 55 Years to 91 Years. Per ClinicalTrials.gov, last updated 2019-08-21.

Sponsored by Central Arkansas Veterans Healthcare System · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
55 Years to 91 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,941 studies in Alzheimer Disease with a site in United States — 346 open to participants now, 444 under way, 40 of them phase 3. Alzheimer Disease · United States.

Enrollment
1,279th of 1,610
20 · median 73
Started
2014
with 53 others
Phase 4
60 of 1,941
7 open now
Registered
647th of 1,941
by date

Among the 1,941 studies in Alzheimer Disease with a site in United States, this one is the 1,279th largest by enrollment of the 1,610 interventional ones that give a count, is one of 54 that started in 2014, is one of 60 in phase 4, and was the 647th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

346 of the 1,941 studies in Alzheimer Disease with a site in United States are open now. Recruiting first, the newest first:

341 more — sign in →

All 346 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 55 Years to 91 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,941 studies in Alzheimer Disease with a site in United States, or all of them as a file.
02

Study summary

Alzheimer's Dementia (AD) is a major public health problem. Apathy, a profound loss of motivation, is seen in majority of patients with AD. Dysfunction of the front of the brain and loss of dopamine, a type of neurochemical, in this part of brain results in apathy. Presence of apathy is linked to deficits in planning sequential tasks such as keeping a routine. Patients with apathy have poor physical function and their caregivers experience extra burden. Unfortunately there are no good medications to treat apathy. FDA has approved the use of brain stimulation by a magnet known as repetitive transcranial magnetic stimulation (rTMS), for treatment of depression. rTMS increases dopamine when applied to frontal lobe of brain so we propose that rTMS would be a good treatment option for apathy in AD. Study hypotheses include that rTMS to the dorsolateral prefrontal cortex (DLPFC) will improve apathy and executive function better than sham treatment in those with AD.

Read the detailed description

Objective: Alzheimer's Dementia (AD) is a major public health problem. Apathy, a profound loss of motivation, is seen in majority of patients with AD. Dysfunction of the front of the brain and loss of dopamine, a type of neurochemical, in this part of brain results in apathy. Presence of apathy is linked to deficits in planning sequential tasks such as keeping a routine. Patients with apathy have poor physical function and their caregivers experience extra burden. Unfortunately there are no good medications to treat apathy. FDA has approved the use of brain stimulation by a magnet known as repetitive transcranial magnetic stimulation (rTMS), for treatment of depression. rTMS increases dopamine when applied to frontal lobe of brain so we propose that rTMS would be a good treatment option for apathy in AD.

Specific Aims: To determine the efficacy of rTMS to the dorsolateral prefrontal cortex (DLPFC) in treating apathy in mild AD in comparison to sham treatment.

  • To compare the efficacy of rTMS to the DLPFC on executive function in mild AD in comparison to sham treatment.

Research Plan: Current study is a prospective randomized sham controlled study of daily rTMS.

Methods: Up to 500 subjects will be pre-screened to enroll 100 subjects for screening and randomizing up to 50 subjects to analyze 20 completers. Subjects with mild AD and apathy will be randomly assigned to rTMS or sham treatment after consent. All subjects will be tested for memory, behavioral problems, functioning and caregiver burden. Apathy will be assessed using the Apathy Evaluation Scale. Memory, executive function, functional status and caregiver burden will be assessed. Subjects will receive daily treatments for 4 weeks with either rTMS or sham coil for a total of 20 treatments. Neither the subject nor the investigators will know which treatment the subject is receiving. Testing will be repeated at the end of 4 weeks and at 8 and 12 weeks after treatment.

03

Conditions studied

  • Apathy
  • Alzheimer's Dementia

Browse trials for

Keywords

  • apathy
  • Alzheimer's
  • executive function
04

Who can participate

Ages eligible
55 Years to 91 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects age ≥ 55 years,
  2. Diagnosis of Alzheimer's dementia meeting the TR criteria,
  3. Apathy Evaluation Scale-Clinician (AES-C) score of ≥ 30,
  4. Mini Mental Status Examination () ≥ 18,
  5. Subjects who clear the TMS adult safety scale (TASS)
  6. On stable dose of antidepressants or dementia medicines (if applicable) for at least two months

Exclusion criteria

Exclusion Criteria:

  1. Subjects taking medications known to increase the risk of seizures from the 2012 Beers criteria: Bupropion, chlorpromazine, clozapine, maprotiline, olanzapine, thioridazine, thiothixene, and tramadol.
  2. Subjects taking medications known to increase seizure threshold not listed in the Beers criteria but in the opinion of PI increase seizure threshold: tricyclic antidepressants, theophylline, methylphenidate, and high-dose thyroid supplementation.
  3. Subjects taking ototoxic medications: Aminoglycosides, Cisplatin.
  4. Subjects in current episode of major depression
  5. History of bipolar disorder
  6. Subjects with history of seizure or first degree relative with seizure disorder
  7. Subjects with implanted device: wearable or implantable cardioverter defibrillators, conductive, ferromagnetic, or other magnetic sensitive metals that are implanted or are non-removable within 30 cm of the treatment coil or those with cochlear implants
  8. Subjects with diagnosis of current alcohol related problems
  9. Subjects with history of stroke , aneurysm, or cranial neurosurgery
  10. Any condition that in the opinion of the study physician is likely to compromise their ability to safely participate in the study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
20 participants (actual)

Study arms

  • Active comparator
    transcranial magnetic stimulator

    Neurostar repetitive transcranial magnetic stimulator. The active procedure will stimulate at 120% motor threshold for 4 seconds at a frequency of 10 Hz, with an inter-train interval of 26 seconds for a total of 3,000 pulses. 20 treatment sessions are given over a four week period.

    Device: Neurostar repetitive transcranial magnetic stimulator

  • Sham comparator
    Sham coil treatment

    Neurostar repetitive transcranial magnetic stimulator. 20 treatments identical in duration will be administered over a four week period.

    Device: Neurostar repetitive transcranial magnetic stimulator

Interventions

  • DeviceNeurostar repetitive transcranial magnetic stimulator

    The active procedure will stimulate at 120% motor threshold for 4 seconds at a frequency of 10 Hz, with an inter-train interval of 26 seconds for a total of 3,000 pulses. 20 treatment sessions are given over a four week period.

    Also known as: •rTMS

06

What researchers measure

Primary outcomes

  1. Apathy Evaluation Scale (AES)

    AES is an 18-item scale that assesses apathy in behavioral, cognitive and emotional domains over the previous four weeks.

    Time frame: 4 weeks

Secondary outcomes

  1. Trials making test

    Widely used test for assessment of executive function.

    Time frame: 4 weeks

Other outcomes

  1. Exit 25

    EXIT-25 is a bedside measure of executive function. It defines the behavioral sequelae of executive dyscontrol and provides a standardized clinical encounter in which they can be observed.

    Time frame: 4 weeks

07

Study locations

1 site
  • Central Arkansas Veterans Healthcare System
    Little Rock, Arkansas 72205, United States
08

References and documents

Publications

  • Padala PR, Boozer EM, Lensing SY, Parkes CM, Hunter CR, Dennis RA, Caceda R, Padala KP. Neuromodulation for Apathy in Alzheimer's Disease: A Double-Blind, Randomized, Sham-Controlled Pilot Study. J Alzheimers Dis. 2020;77(4):1483-1493. doi: 10.3233/JAD-200640. PubMed 32925060 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2014 to primary completion in May 2019, 60 months.

Of 42 phase 4 interventional studies under Alzheimer Disease, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 67. This study's 60 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2014
First posted
Jul 15, 2014
StartActual
May 2014
Primary completionActual
May 2019
CompletionActual
Jul 2019
Last update
Aug 21, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02190084
Lead sponsor
Central Arkansas Veterans Healthcare System
Responsible party
Prasad R. Padala (Associate Director for clinical programs, GRECC, Central Arkansas Veterans Healthcare System) — Principal investigator
First posted
Jul 15, 2014
Start date
May 2014
Primary completion
May 2019
Completion
Jul 2019
Last update
Aug 21, 2019

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion